625 related articles for article (PubMed ID: 29089371)
21. Deficiency of Both Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Exacerbated Liver Fibrosis in Mice.
Ferrell JM; Pathak P; Boehme S; Gilliland T; Chiang JYL
Hepatology; 2019 Sep; 70(3):955-970. PubMed ID: 30664797
[TBL] [Abstract][Full Text] [Related]
22. Farnesoid X receptor (FXR) agonist ameliorates systemic insulin resistance, dysregulation of lipid metabolism, and alterations of various organs in a type 2 diabetic kidney animal model.
Han SY; Song HK; Cha JJ; Han JY; Kang YS; Cha DR
Acta Diabetol; 2021 Apr; 58(4):495-503. PubMed ID: 33399988
[TBL] [Abstract][Full Text] [Related]
23. Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet α Cells to Promote Glucose Homeostasis.
Kumar DP; Asgharpour A; Mirshahi F; Park SH; Liu S; Imai Y; Nadler JL; Grider JR; Murthy KS; Sanyal AJ
J Biol Chem; 2016 Mar; 291(13):6626-40. PubMed ID: 26757816
[TBL] [Abstract][Full Text] [Related]
24. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism.
Zheng X; Chen T; Jiang R; Zhao A; Wu Q; Kuang J; Sun D; Ren Z; Li M; Zhao M; Wang S; Bao Y; Li H; Hu C; Dong B; Li D; Wu J; Xia J; Wang X; Lan K; Rajani C; Xie G; Lu A; Jia W; Jiang C; Jia W
Cell Metab; 2021 Apr; 33(4):791-803.e7. PubMed ID: 33338411
[TBL] [Abstract][Full Text] [Related]
25. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.
Jiang T; Wang XX; Scherzer P; Wilson P; Tallman J; Takahashi H; Li J; Iwahashi M; Sutherland E; Arend L; Levi M
Diabetes; 2007 Oct; 56(10):2485-93. PubMed ID: 17660268
[TBL] [Abstract][Full Text] [Related]
26. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
27. Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.
You H; Gao T; Raup-Konsavage WM; Cooper TK; Bronson SK; Reeves WB; Awad AS
Kidney Int; 2017 Mar; 91(3):671-682. PubMed ID: 27914709
[TBL] [Abstract][Full Text] [Related]
28. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice.
Wu H; Liu G; He Y; Da J; Xie B
Eur J Pharmacol; 2019 Sep; 858():172393. PubMed ID: 31085240
[TBL] [Abstract][Full Text] [Related]
29. Low-Dose IL-17 Therapy Prevents and Reverses Diabetic Nephropathy, Metabolic Syndrome, and Associated Organ Fibrosis.
Mohamed R; Jayakumar C; Chen F; Fulton D; Stepp D; Gansevoort RT; Ramesh G
J Am Soc Nephrol; 2016 Mar; 27(3):745-65. PubMed ID: 26334030
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation.
Miyazaki-Anzai S; Masuda M; Kohno S; Levi M; Shiozaki Y; Keenan AL; Miyazaki M
J Lipid Res; 2018 Sep; 59(9):1709-1713. PubMed ID: 29976576
[TBL] [Abstract][Full Text] [Related]
31. INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function.
Comeglio P; Cellai I; Mello T; Filippi S; Maneschi E; Corcetto F; Corno C; Sarchielli E; Morelli A; Rapizzi E; Bani D; Guasti D; Vannelli GB; Galli A; Adorini L; Maggi M; Vignozzi L
J Endocrinol; 2018 Aug; 238(2):107-127. PubMed ID: 29945982
[TBL] [Abstract][Full Text] [Related]
32. The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance.
Yan X; Li P; Tang Z; Feng B
BMC Endocr Disord; 2017 Sep; 17(1):60. PubMed ID: 28946907
[TBL] [Abstract][Full Text] [Related]
33. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
[TBL] [Abstract][Full Text] [Related]
34. Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
Wang W; Qiu L; Howard A; Solis N; Li C; Wang X; Kopp JB; Levi M
J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):384-95. PubMed ID: 25031296
[TBL] [Abstract][Full Text] [Related]
35. Farnesoid X Receptor Agonism Protects against Diabetic Tubulopathy: Potential Add-On Therapy for Diabetic Nephropathy.
Marquardt A; Al-Dabet MM; Ghosh S; Kohli S; Manoharan J; ElWakiel A; Gadi I; Bock F; Nazir S; Wang H; Lindquist JA; Nawroth PP; Madhusudhan T; Mertens PR; Shahzad K; Isermann B
J Am Soc Nephrol; 2017 Nov; 28(11):3182-3189. PubMed ID: 28696246
[TBL] [Abstract][Full Text] [Related]
36. Bile acid receptors in non-alcoholic fatty liver disease.
Li Y; Jadhav K; Zhang Y
Biochem Pharmacol; 2013 Dec; 86(11):1517-24. PubMed ID: 23988487
[TBL] [Abstract][Full Text] [Related]
37. New insights in the multiple roles of bile acids and their signaling pathways in metabolic control.
de Boer JF; Bloks VW; Verkade E; Heiner-Fokkema MR; Kuipers F
Curr Opin Lipidol; 2018 Jun; 29(3):194-202. PubMed ID: 29553998
[TBL] [Abstract][Full Text] [Related]
38. Liver X receptors preserve renal glomerular integrity under normoglycaemia and in diabetes in mice.
Patel M; Wang XX; Magomedova L; John R; Rasheed A; Santamaria H; Wang W; Tsai R; Qiu L; Orellana A; Advani A; Levi M; Cummins CL
Diabetologia; 2014 Feb; 57(2):435-46. PubMed ID: 24201575
[TBL] [Abstract][Full Text] [Related]
39. Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists.
Miyata S; Kawashima Y; Sakai M; Matsubayashi M; Motoki K; Miyajima Y; Watanabe Y; Chikamatsu N; Taniguchi T; Tokuyama R
Sci Rep; 2021 Apr; 11(1):9196. PubMed ID: 33911126
[TBL] [Abstract][Full Text] [Related]
40. Gentiopicroside activates the bile acid receptor Gpbar1 (TGR5) to repress NF-kappaB pathway and ameliorate diabetic nephropathy.
Xiao H; Sun X; Liu R; Chen Z; Lin Z; Yang Y; Zhang M; Liu P; Quan S; Huang H
Pharmacol Res; 2020 Jan; 151():104559. PubMed ID: 31759089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
